Hear it First from our team of Data Science Experts
Validation software has traditionally always been a source of great frustration for CROs and small/medium Pharma companies. Investing in and maintaining a validated statistical computing..
Validation. A crucial element of the pharmaceutical industry that ensures compliance, protects consumers and ultimately, saves lives. But while it’s undoubtedly a positive part of the process,..
Why should you attend?
CBI’s 5th Annual Clinical Data Disclosure and Transparency conference will help to navigate regulatory changes at both the U.S. and international level. Develop strategies..
d-Wise appoints VP of d-Wise Europe and establishes German office in response to rapid international growth
- Demand for d-Wise’s clinical trials de-identification solutions soars following new regulatory demands in Europe
- The strategic choice of Frankfurt puts d-Wise in the centre of a major pharmaceutical..
As the life sciences industry prepares for compliance with EMA Policy 0070 and its requirements for the anonymization of shared clinical study reports, d-Wise has been previewing its powerful Blur..
The latest version of the software, Blur CSR (due for release in December), offers enhanced risk management plus new controls for medical writers producing clinical study reports. (d-Wise booth at..
The Solution Landscape Part 1: CDR
A few weeks ago, we raised the subject of clinical data repositories (CDRs) in a LinkedIn discussion and a subsequent blog about spawning acronyms in the clinical..